Open Access

Antibiotic susceptibility of Atopobium vaginae

  • Ellen De Backer1Email author,
  • Rita Verhelst1,
  • Hans Verstraelen2,
  • Geert Claeys1,
  • Gerda Verschraegen1,
  • Marleen Temmerman2 and
  • Mario Vaneechoutte1
BMC Infectious DiseasesBMC series ¿ open, inclusive and trusted20066:51

DOI: 10.1186/1471-2334-6-51

Received: 20 November 2005

Accepted: 16 March 2006

Published: 16 March 2006

Abstract

Background

Previous studies have indicated that a recently described anaerobic bacterium, Atopobium vaginae is associated with bacterial vaginosis (BV). Thus far the four isolates of this fastidious micro-organism were found to be highly resistant to metronidazole and susceptible for clindamycin, two antibiotics preferred for the treatment of BV.

Methods

Nine strains of Atopobium vaginae, four strains of Gardnerella vaginalis, two strains of Lactobacillus iners and one strain each of Bifidobacterium breve, B. longum, L. crispatus, L. gasseri and L. jensenii were tested against 15 antimicrobial agents using the Etest.

Results

All nine strains of A. vaginae were highly resistant to nalidixic acid and colistin while being inhibited by low concentrations of clindamycin (range: < 0.016 μg/ml), rifampicin (< 0.002 μg/ml), azithromycin (< 0.016 – 0.32 μg/ml), penicillin (0.008 – 0.25 μg/ml), ampicillin (< 0.016 – 0.94 μg/ml), ciprofloxacin (0.023 – 0.25 μg/ml) and linezolid (0.016 – 0.125 μg/ml). We found a variable susceptibility for metronidazole, ranging from 2 to more than 256 μg/ml. The four G. vaginalis strains were also susceptible for clindamycin (< 0.016 – 0.047 μg/ml) and three strains were susceptible to less than 1 μg/ml of metronidazole. All lactobacilli were resistant to metronidazole (> 256 μg/ml) but susceptible to clindamycin (0.023 – 0.125 μg/ml).

Conclusion

Clindamycin has higher activity against G. vaginalis and A. vaginae than metronidazole, but not all A. vaginae isolates are metronidazole resistant, as seemed to be a straightforward conclusion from previous studies on a more limited number of strains.

Background

Bacterial vaginosis is considered a common vaginal disorder in women of reproductive age. Whereas normal vaginal microflora consists of lactobacilli, especially L. crispatus [14], the disturbed vaginal microflora is characterized by the overgrowth of Gardnerella vaginalis and anaerobic bacteria such as Mobiluncus spp., Mycoplasma hominis and Prevotella spp. Recently several research groups showed – by means of cloning of the 16S rRNA-gene [3, 5], by Terminal Restriction Fragment Length Polymorphism analysis of the 16S rRNA gene (T-RFLP) [6, 7], by specific PCR [5, 8, 9], by Denaturing Gradient Gel Electrophoresis of the 16S rRNA gene (DGGE) [10] and by FISH [3, 11] – that a previously unrecognized organism, Atopobium vaginae, was strongly associated with bacterial vaginosis and with Gardnerella vaginalis.

During the last decade, the interest for bacterial vaginosis increased because of reports of adverse sequelae of this disorder, such as preterm birth [1214], pelvic inflammatory disease [15, 16] and postpartum endometritis [17]. In addition, several publications showed that an altered vaginal microflora is linked to an increased susceptibility to the acquisition of HIV [18, 19] and other sexually transmitted infectious agents such as Neisseria gonorrhoeae and Chlamydia trachomatis [18, 20].

The severity of the consequences of such sequelae asks for an adequate treatment of bacterial vaginosis. Currently the preferred antibiotic treatment regimen consists of clindamycin or metronidazole (oral or intravaginal). Recurrence rates of up to 30% within 3 months after treatment have been reported [21, 22]. This recurrence might be due to the survival of metronidazole or clindamycin resistant bacteria in the vagina, although Beigi et al. [23] showed recently that less than one percent of the cultivable vaginal anaerobic bacteria is resistant to metronidazole.

Another possible explanation might be the presence of some fastidious to unculturable, metronidazole resistant organism, a role for which A. vaginae is a likely candidate, since Geißdörfer et al. [24] and Ferris et al. [10] reported an MIC of > 32 μg/ml for metronidazole for the four isolates that were tested.

Here, we studied the susceptibility of nine other A. vaginae isolates for 15 antimicrobial agents by using the Etest and for comparison we included a limited number of other important vaginal bacteria such as lactobacilli, G. vaginalis and bifidobacteria and we compared our results with those of previously published articles.

Methods

Nine strains of Atopobium vaginae, four strains of Gardnerella vaginalis, two strains of Lactobacillus iners and one strain each of Bifidobacterium breve, B. longum, Lactobacillus crispatus, L. gasseri and L. jensenii were tested against 15 antibiotics (ampicillin, azithromycin, bacitracin, cefuroxime, ciprofloxacin, clindamycin, colistin, doxycycline, kanamycin, linezolid, metronidazole, nalidixic acid, penicillin, rifampicin and vancomycin) [see Additional file 1]. Six strains of A. vaginae (CCUG 42099, CCUG 44116, CCUG 44258, CCUG 38953T, CCUG 44125, CCUG 44061) were kindly provided by the Culture Collection of Göteborg (Sweden). The other strains were obtained from studies by cultivating vaginal samples (with informed consent) and identified by tDNA-PCR and 16S rRNA gene sequencing [4].

Strains were cultivated anaerobically using the GasPak anaerobic envelope system (Becton Dickinson, Erembodegem, Belgium) at 37°C on Trypticase Soy Agar (TSA) + 5 % sheep blood (Becton Dickinson). Epsilometer tests (Etest AB Biodisk, Solna, Sweden) were used to determine the minimal inhibitory concentrations (MIC). An inoculum taken from TSA + 5% sheep blood was suspended in 0.5 ml of physiological water and adjusted to the turbidity of a 1 McFarland standard. Before inoculating the plates and testing for metronidazole, plates were anaerobically incubated during 24 h. After application of the epsilometer, test plates were anaerobically incubated at 37°C. The inhibitory concentration was defined as the value on the test strip scale at which the inhibition zone intersected the strip edge, according to the manufacturers' instructions. MIC-values were read after 48 h for G. vaginalis, Lactobacillus spp. and Bifidobacterium spp. and after 72 h for A. vaginae.

Results and discussion

Value and reproducibility of Etest for MIC-determination of anaerobes

In this study we used the Etest for MIC-determination of vaginal bacteria towards 15 antibiotics. Croco et al. [25] concluded, from a study whereby the Etest was compared with the reference agar dilution method, that the Etest was a quantitatively accurate and reproducible method for routinely testing the antimicrobial susceptibilities of anaerobes, in particular of organisms associated with BV. Discordances were reported only for clindamycin susceptibility testing of lactobacilli and chloramphenicol susceptibility testing of the Bacteroides fragilis group. Schieven et al. [26] reported an agreement between the Etest and the reference agar dilution method within 1 log2 dilution of 87.4% for clindamycin and 85.1% for metronidazole for a total of 150 anaerobic isolates tested.

Antimicrobial susceptibility testing of Atopobium vaginae

The antibiotic susceptibility for ampicillin, azithromycin, bacitracin, cefuroxime, ciprofloxacin, clindamycin, colistin, doxycycline, kanamycin, linezolid, metronidazole, nalidixic acid, penicillin, rifampicin and vancomycin obtained for nine Atopobium vaginae isolates in this study is listed in additional file 1 [see Additional file 1].

We focused our research on the antibiotic susceptibility profile of Atopobium vaginae. In contrast to the results of Ferris et al. [10] and Geißdörfer et al. [24], who reported MIC-values of more than 32 μg/ml for all four A. vaginae isolates tested (Table 1), we found a great variability in susceptibility for metronidazole, ranging from 2 to more than 256 μg/ml. When taking into account 16 μg/ml as the breakpoint between sensitive and resistant (NCCLS guidelines), only four out of 9 strains in our study could be accounted as intermediately susceptible or resistant. All nine A. vaginae isolates in our study showed MIC-values of more than 256 μg/ml for nalidixic acid and colistin while being inhibited by low concentrations of clindamycin (range: < 0.016 μg/ml), rifampicin (< 0.002 μg/ml), azithromycin (< 0.016 – 0.32 μg/ml), penicillin (0.008 – 0.25 μg/ml), ampicillin (< 0.016 – 0.94 μg/ml), ciprofloxacin (0.023 – 0.25 μg/ml) and linezolid (0.016 – 0.125 μg/ml) (Table 1).
Table 1

Comparison of MIC-values as determined for Atopobium vaginae by Ferris et al. [8] and Geißdörfer et al. [24] and in this study.

 

This study

Geißdörfer et al. [24]a

Ferris et al. [8]b

Number of strains

9

1

3

Antimicrobial agent

MIC50c

Rangec

MICc

Rangec

Ampicillin

0.023

< 0.016 – 0.94

0.032

 

Ampicillin/sulbactam

   

0.06 – 0.25

Azitromycin

< 0.016

< 0.016 – 0.32

  

Bacitracin

3

1 – 4

  

Cefoxitin

  

2

2

Ceftriaxone

   

0.5 – 2

Cefuroxime

0.125

0.016 – 0.25

0.19

 

Ciprofloxacin

0.064

0.023 – 0.25

  

Clindamycin

< 0.016

< 0.016

 

< 0.015

Colistin

> 1024

> 1024

  

Doxycyclin

0.38

0.19 – 0.75

  

Imipenem

  

0.016

< 0.015 – 0.5

Kanamycin

12

8 – 16

  

Linezolid

0.047

0.016 – 0.125

 

0.06 – 0.25

Meropenem

   

< 0.015 – 0.5

Metronidazole

8

2 - > 256

>16

> 32

Moxifloxacin

   

0.06 – 1

Nalidixic acid

> 256

> 256

  

Penicillin

0.094

0.008 – 0.25

0.125

 

Rifampicin

< 0.002

< 0.002

  

Trovafloxacin

   

< 0.015 – 2

Vancomycin

1.5

1 – 4

  

Legend

a. Tested with Etest and agar dilution method.

b. Tested with broth microdilution method for anaerobic bacteria with Brucella Broth supplemented with vitamin K (1 μg/ml), hemin (5 μg/ml) and laked horse blood (5%).

c. Data in μg/ml.

We previously described the existence of a second genotype within A. vaginae. To this genotype belongs isolate PB2003/189-T1-4, of which the 16S rRNA gene sequence differs at 23 positions compared to the type strain, but is identical to that of an isolate no longer in our collection of which the sequence was submitted [Genbank: AJ585206] [5]. This genotype 2 isolate showed a marked difference only for azithromycin (i.e. MIC of 0.32 μg/ml) with the other isolates (MIC of < 0.016 μg/ml).

Antimicrobial susceptibility testing of Gardnerella vaginalis

We tested 4 strains of Gardnerella vaginalis. By using the Etest method in an anaerobic environment we found in general slightly lower values for ampicillin (range: < 0.016 – 0.047 μg/ml), penicillin (0.004 – 0.047 μg/ml), cefuroxim (< 0.016 – 0.125 μg/ml) and rifampicin (0.5 – 0.75 μg/ml) (Table 1), compared to other publications [25, 27, 28] [see Additional file 2]. The range of the MIC-values of Gardnerella vaginalis for clindamycin (range: < 0.016 – 0.047 μg/ml), colistin (> 1024 μg/ml), doxycycline (0.25 – 32 μg/ml), kanamycin (16 – 32 μg/ml), metronidazole (0.75 – 16 μg/ml), nalidixic acid (> 256 μg/ml) and vancomycin (0.125 – 0.38 μg/ml) is comparable with other studies [25, 2731] [see Additional file 2]. G. vaginalis is, according to NCCLS standards for anaerobic bacteria, susceptible to ampicillin (range: < 0.016 – 0.047 μg/ml), penicillin (0.004 – 0.047 μg/ml) and azithromycin (< 0.016 – 0.047 μg/ml). In 1993, Goldstein et al. [29] reported that 20% of G. vaginalis strains were resistant to metronidazole (MIC ≥ 16 μg/ml). In 2002, the same group reported a resistance of 29% to metronidazole for G. vaginalis [30]. All four strains in our study were susceptible.

Antimicrobial susceptibility testing of Lactobacillusspp

Most of the Lactobacillus spp. we tested show a low MIC-value for ampicillin (range for all lactobacilli: 0.064 – 0.5 μg/ml), azithromycin (0.023 – 0.125 μg/ml), cefuroxim (< 0.016 – 1 μg/ml), linezolid (0.19 – 1.5 μg/ml), penicillin (0.047 – 0.19 μg/ml), rifampicin (0.016 – 2 μg/ml) and vancomycin (0.38 – 1 μg/ml) [see Additional file 1]. All strains were resistant to metronidazole (range for all lactobacilli: > 256 μg/ml). The strains of the species L. crispatus, L. jensenii and L. gasseri were all highly resistant to ciprofloxacin (range: > 32 μg/ml) in contrast to both L. iners strains (range: 0.25 – 0.38 μg/ml).

The single strain of L. crispatus tested yielded a very low MIC-value for clindamycin (< 0.016 μg/ml) and a high MIC-value for rifampicin compared to the other lactobacilli. The strain of L. gasseri tested showed comparable results to those of previous publications [32, 33] for clindamycin, metronidazole, penicillin and vancomycin [see Additional file 2], indicating that this species is much more resistant to clindamycin than L. crispatus.

All lactobacilli were resistant to metronidazole (> 256 μg/ml) but susceptible for clindamycin (0.023 – 0.125 μg/ml). There were no literature data to compare the susceptibility of L. iners and L. jensenii for the antimicrobial agents tested in this study.

Antimicrobial susceptibility testing of Bifidobacteriumspp

Both of the tested Bifidobacterium strains are sensitive to a low amount of ampicillin (B. longum: 0.25 μg/ml, B. breve: 0.38 μg/ml), azithromycin (B. longum: 0.064 μg/ml, B. breve: 0.25 μg/ml), clindamycin (B. breve and B. longum: < 0.016 μg/ml), linezolid (B. longum: 0.25 μg/ml, B. breve: 0.38 μg/ml), penicillin (B. longum: 0.19 μg/ml, B. breve: 0.5 μg/ml), rifampicin (B. longum: 0.25 μg/ml, B. breve: 0.19 μg/ml) and vancomycin (B. longum: 0.38 μg/ml, B. breve: 1 μg/ml) [see Additional file 1]. The strains tested showed comparable results with previous publications except for linezolid and kanamycin [see Additional file 2], where we obtained a lower value than described [3335].

Conclusion

Bacterial vaginosis is a polymicrobial disease and the organisms involved are likely to be in symbiotic relationship to each other for various metabolic requirements. Antimicrobial treatment may affect susceptible members of the consortia which may negatively alter the microenvironment for resistant organisms, such as A. vaginae and G. vaginalis.

By knowing the antibiotic susceptibility of the vaginal species it might be possible to develop new regimens for the treatment of recurrent bacterial vaginosis.

For example, this study showed that metronidazole resistance of A. vaginae is not an intrinsic feature. Further research needs to make clear whether this metronidazole resistance might be acquired by the presence and activation of nim-genes [36]. Metronidazole resistance up to 29% [30] has been described for G. vaginalis but mechanisms are not yet clarified. Possibly this could be due to the lack of nitroreductases necessary to produce the hydroxymetabolite of metronidazole, which has stronger antibiotic activity than the parent compound.

Lactobacilli are resistant to metronidazole and it has been demonstrated that recolonistation of the vagina by H2O2-producing lactobacilli after metronidazole treatment occurs more frequently compared to clindamycin treatment [37].

Clindamycin, which is frequently used as a treatment for bacterial vaginosis, has indeed higher activity against G. vaginalis and A. vaginae than metronidazole, but L. crispatus is more susceptible to clindamycin than L. gasseri with as a consequence that a regimen of clindamycin can remove also the H2O2-producing lactobacilli from the vaginal microflora (Table 2). Hydrogen peroxide production is generally believed to be an important factor in the preservation of a normal vaginal microflora [1], i.e. in the build up of vaginal colonisation resistance. Therefore, it is possible that clindamycin treatment may diminish the vaginal colonisation resistance. Moreover, resistance to clindamycin seems to develop more readily than resistance to metronidazole, as becomes apparent from clinical studies comparing both antibiotics [23, 37].
Table 2

Overview of the MIC-value ranges for Atopobium vaginae and Gardnerella vaginalis for 15 antimicrobial agents.

 

Atopobium vaginae (n = 9)

Gardnerella vaginalis (n = 4)

Antimicrobial agent

Rangea

Rangea

Ampicillin

< 0.016 – 0.94

< 0.016 – 0.047

Azithromycin

< 0.016 – 0.32

< 0.016 – 0.047

Bacitracin

1 – 4

0.75 – 2

Cefuroxim

0.016 – 0.25

< 0.016 – 0.125

Ciprofloxacin

0.023 – 0.25

0.75 – 2

Clindamycin

< 0.016

< 0.016 – 0.047

Colistin

> 1024

> 1024

Doxycycline

0.19 – 0.75

0.25 – 32

Kanamycin

8 – 16

16 – 32

Linezolid

0.016 – 0.125

0.125 – 0.19

Metronidazole

2 – 256

0.75 – 16

Nalidixic acid

> 256

> 256

Penicillin

0.008 – 0.25

0.004 – 0.047

Rifampicin

< 0.002

0.5 – 0.75

Vancomycin

1 – 4

0.125 – 0.38

Legend

a. Data in μg/ml.

Declarations

Acknowledgements

This work was supported through a research grant of the Bijzonder Onderzoeksfonds of the University of Gent (UGent) and the Fund for Scientific Research Flanders (Belgium). We thank the Culture Collection of the University of Göteborg, Sweden for kindly providing Atopobium vaginae isolates.

Authors’ Affiliations

(1)
Department of Clinical Chemistry, Microbiology & Immunology, Ghent University Hospital, UGent
(2)
Department of Obstetrics & Gynaecology, Ghent University Hospital, UGent

References

  1. Antonio MA, Hawes SE, Hillier SL: The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. J Infect Dis. 1999, 180: 1950-1956. 10.1086/315109.View ArticlePubMed
  2. Vallor AC, Antonio MA, Hawes SE, Hillier SL: Factors associated with acquisition of, or persistent colonization by, vaginal lactobacilli: role of hydrogen peroxide production. J Infect Dis. 2001, 184: 1431-1436. 10.1086/324445.View ArticlePubMed
  3. Fredricks DN, Fiedler TL, Marrazzo JM: Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005, 353: 1899-1911. 10.1056/NEJMoa043802.View ArticlePubMed
  4. Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Van Simaey L, De Ganck C, De Backer E, Temmerman M, Vaneechoutte M: Comparison between Gram stain and culture for the characterization of vaginal microflora: Definition of a distinct grade that resembles grade I microflora and revised categorization of grade I microflora. BMC Microbiol. 2004, 5: 61-10.1186/1471-2180-5-61.View Article
  5. Verhelst R, Verstraelen H, Claeys G, Verschraegen G, Delanghe J, Van Simaey L, De Ganck C, Temmerman M, Vaneechoutte M: Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiol. 2004, 4: 16-10.1186/1471-2180-4-16.PubMed CentralView ArticlePubMed
  6. Verhelst R, Verstraelen H, De Backer E, Claeys G, Verschraegen G, Van Simaey L, De Ganck C, Temmerman M, Vaneechoutte M: Characterization of vaginal microflora at three time points in pregnancy by Gram stain, culture and T-RFLP identifies L. gasseri as the Lactobacillus species most present in bacterial vaginosis. Submitted to BMC infectious diseases.
  7. Verstraelen H, Verhelst R, Claeys G, Temmerman M, Vaneechoutte M: Culture-independent analysis of vaginal microflora: the unrecognized association of Atopobium vaginae with bacterial vaginosis. Am J Obstet Gynecol. 2004, 191: 1130-1132. 10.1016/j.ajog.2004.04.013.View ArticlePubMed
  8. Ferris MJ, Masztal A, Aldridge KE, Fortenberry JD, Fidel PL Jr, Martin DH: Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis. 2004, 4: 5-10.1186/1471-2334-4-5.PubMed CentralView ArticlePubMed
  9. Burton JP, Chilcott CN, Al-Qumber M, Brooks HJ, Wilson D, Tagg JR, Devenish C: A preliminary survey of Atopobium vaginae in women attending the Dunedin gynaecology out-patients clinic: Is the contribution of the hard-to-culture microbiota overlooked in gynaecological disorders?. Aust N Z J Obstet Gynaecol. 2005, 45: 450-452. 10.1111/j.1479-828X.2005.00456.x.View ArticlePubMed
  10. Ferris MJ, Masztal A, Martin DH: Use of species-directed 16S rRNA gene PCR primers for detection of Atopobium vaginae in patients with bacterial vaginosis. J Clin Microbiol. 2004, 42: 5892-5894. 10.1128/JCM.42.12.5892-5894.2004.PubMed CentralView ArticlePubMed
  11. Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S, Hale LP, Lochs H: Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005, 106: 1013-1023.View ArticlePubMed
  12. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J: Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. Brit Med J. 1994, 308: 295-298.PubMed CentralView ArticlePubMed
  13. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, Klebanoff MA: Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med. 1995, 333: 1737-1742. 10.1056/NEJM199512283332604.View ArticlePubMed
  14. Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P: Bacterial vaginosis as a risk factor for preterm delivery: A meta-analysis. Am J Obstet Gynecol. 2003, 189: 139-147. 10.1067/mob.2003.339.View ArticlePubMed
  15. Haggerty CL, Hillier SL, Bass DC, Ness RB: PID evaluation and clinical health study investigators. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis. 2004, 39: 990-995. 10.1086/423963.View ArticlePubMed
  16. Ness RB, Kip KE, Hillier SL, Soper DE, Stamm CA, Sweet RL, Rice P, Richter HE: A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005, 162: 585-590. 10.1093/aje/kwi243.View ArticlePubMed
  17. Watts DH, Krohn MA, Hillier SL, Eschenbach DA: Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol. 1990, 75: 52-58.PubMed
  18. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, Mandaliya K, Ndinya-Achola JO, Bwayo J, Kreiss J: Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis. 1999, 180: 1863-1868. 10.1086/315127.View ArticlePubMed
  19. Sewankambo N, Gray RH, Wawer MJ, Paxton L, McNaim D, Wabwire-Mangen F, Serwadda D, Li C, Kiwanuka N, Hillier SL, Rabe L, Gaydos CA, Quinn TC, Konde-Lule J: HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet. 1997, 350: 546-550. 10.1016/S0140-6736(97)01063-5.View ArticlePubMed
  20. Hawes SE, Hillier SL, Benedetti J, Stevens CE, Koutsky LA, Wolner-Hanssen P, Holmes KK: Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis. 1996, 174: 1058-1063.View ArticlePubMed
  21. Hay P: Recurrent bacterial vaginosis. Curr Infect Dis Rep. 2000, 2: 506-512.View ArticlePubMed
  22. Larsson PG, Forsum U: Bacterial vaginosis, a disturbed bacterial flora and treatment enigma. APMIS. 2005, 113: 305-316. 10.1111/j.1600-0463.2005.apm_113501.x.View ArticlePubMed
  23. Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL: Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol. 2004, 191: 1124-1129. 10.1016/j.ajog.2004.05.033.View ArticlePubMed
  24. Geissdorfer W, Bohmer C, Pelz K, Schoerner C, Frobenius W, Bogdan C: Tuboovarian abscess caused by Atopobium vaginae following transvaginal oocyte recovery. J Clin Microbiol. 2003, 41: 2788-2790. 10.1128/JCM.41.6.2788-2790.2003.PubMed CentralView ArticlePubMed
  25. Croco JL, Erwin ME, Jennings JM, Putnam LR, Jones RN: Evaluation of the Etest for antimicrobial spectrum and potency determinations of anaerobes associated with bacterial vaginosis and peritonitis. Diagn Microbiol Infect Dis. 1994, 20: 213-219. 10.1016/0732-8893(94)90006-X.View ArticlePubMed
  26. Schieven BC, Massey VE, Lannigan R, Hussain Z: Evaluation of susceptibility of anaerobic organisms by the Etest and the reference agar dilution method. Clin Infect Dis. 1995, 20: S337-S338.View ArticlePubMed
  27. Kharsany AB, Hoosen AA, Van den Ende J: Antimicrobial susceptibilities of Gardnerella vaginalis. Antimicrob Agents Chemother. 1993, 37: 2733-2735.PubMed CentralView ArticlePubMed
  28. McCarthy LR, Mickelsen PA, Smith EG: Antibiotic susceptibility of Haemophilus vaginalis (Corynebacterium vaginale) to 21 antibiotics. Antimicrob Agents Chemother. 1979, 16: 186-189.PubMed CentralView ArticlePubMed
  29. Goldstein EJ, Citron DM, Cherubin CE, Hillier SH: Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother. 1993, 31: 363-372.View ArticlePubMed
  30. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT: In vitro activities of Garenoxacin(BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother. 2002, 46: 3995-3996. 10.1128/AAC.46.12.3995-3996.2002.PubMed CentralView ArticlePubMed
  31. Jones BM, Geary I, Lee ME, Duerden BI: Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother. 1989, 33: 970-972.PubMed CentralView ArticlePubMed
  32. Danielsen M, Wind A: Susceptibility of Lactobacillus spp. to antimicrobial agents. Int J Food Microbiol. 2003, 82: 1-11. 10.1016/S0168-1605(02)00254-4.View ArticlePubMed
  33. Delgado S, Florez AB, Mayo B: Antibiotic susceptibility of Lactobacillus and Bifidobacterium species from the human gastrointestinal tract. Curr Microbiol. 2005, 50: 202-207. 10.1007/s00284-004-4431-3.View ArticlePubMed
  34. Lim KS, Huh CS, Baek YI: Antimicrobial susceptibility of bifidobacteria. J Dairy Sci. 1993, 76: 2168-2174.View ArticlePubMed
  35. Moubareck C, Gavini F, Vaugien L, Butel MJ, Doucet-Populaire F: Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother. 2005, 55: 38-44. 10.1093/jac/dkh495.View ArticlePubMed
  36. Theron MM, Janse Van Rensburg MN, Chalkley LJ: Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.). J Antimicrob Chemother. 2004, 54: 240-242. 10.1093/jac/dkh270.View ArticlePubMed
  37. Austin MN, Beigi RH, Meyn LA, Hillier SL: Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol. 2005, 43: 4492-4497. 10.1128/JCM.43.9.4492-4497.2005.PubMed CentralView ArticlePubMed
  38. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2334/​6/​51/​prepub

Copyright

© De Backer et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.